淀粉样变性肾病 中国就医指南

Amyloidosis-related nephropathy is a progressive kidney disorder caused by the extracellular deposition of misfolded amyloid proteins—primarily immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, tubulointerstitium, and vasculature of the kidneys. These insoluble fibrillar aggregates disrupt normal renal architecture and function, leading to proteinuria (often nephrotic-range), declining glomerular filtration rate (GFR), hypertension, edema, and ultimately end-stage kidney disease (ESKD) if untreated. Pathogenesis hinges on systemic protein misfolding: in AL amyloidosis, clonal plasma cell dyscrasia produces abnormal light chains that aggregate into β-pleated sheets resistant to proteolysis; in AA amyloidosis, chronic inflammatory conditions (e.g., rheumatoid arthritis, tuberculosis, or familial Mediterranean fever) drive sustained overproduction of serum amyloid A, which fragments and deposits as amyloid. Renal involvement occurs in ~70% of AL amyloidosis cases and up to 90% of AA cases with longstanding inflammation. Epidemiologically, AL amyloidosis has an incidence of 8–12 per million person-years globally, with median age at diagnosis of 65 years; AA amyloidosis is rarer in high-income countries but more prevalent in regions with endemic chronic infections or autoinflammatory disorders. Risk factors include advanced age (>60), monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, chronic inflammatory or infectious diseases, and certain genetic variants (e.g., SAA1 polymorphisms in AA). Early symptoms are often subtle—fatigue, foamy urine, weight gain from edema—but rapidly progress to hypoalbuminemia, hyperlipidemia, acute kidney injury, and thromboembolic complications due to loss of antithrombin and other plasma proteins. Quality of life is profoundly impaired: patients experience physical debilitation from fluid overload and malnutrition, psychological distress from diagnostic uncertainty and treatment toxicity, social isolation due to fatigue and dialysis dependence, and significant financial burden from prolonged monitoring and multidisciplinary care. Without timely intervention, median survival after renal involvement onset is <2 years in untreated AL amyloidosis. Accurate diagnosis requires kidney biopsy with Congo red staining and immunohistochemistry or mass spectrometry-based typing—critical because therapeutic strategies differ fundamentally between AL and AA subtypes. Early referral to specialized nephrology centers with amyloidosis expertise is essential to optimize outcomes.

# 淀粉样变性肾病治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：AL型早期、轻度蛋白尿（<3.5g/d）、eGFR ≥60mL/min/1.73m²，无心/肝多系统受累者。

• •一线药物治疗（含监测）：硼替佐米+地塞米松方案（6周期），费用区间：8.2–12.6万元（含骨髓活检2800元、血清游离轻链检测420元/次×6次、24h尿蛋白定量120元/次×4次、心脏超声320元）。
• •支持治疗：ACEI/ARB控压+利尿+低盐低蛋白饮食管理，年费用约3600–5800元（含随访检验及药费）。

二、核心介入/根治性方案

适用条件：AL型、年龄＜70岁、心功能NYHA I–II级、无严重器官衰竭，符合自体造血干细胞移植（ASCT）指征。

• •ASCT全流程：动员（G-CSF+环磷酰胺）、采集、冻存、清髓预处理（美法仑200mg/m²）、回输及住院监护，总费用区间：24.5–31.8万元（含术前PET-CT 7200元、HLA配型1600元、CD34+细胞计数800元、层流病房日均费1200元×28天）。

三、特殊复杂/晚期方案

适用场景：ATTR型进展期、透析依赖、合并心肌淀粉样变或耐药AL型。

• •靶向药（氯苯唑酸）联合透析维持：年治疗费19.8–22.4万元（氯苯唑酸胶囊1280元/盒×12盒/年，透析费420元/次×3次/周×52周=65,520元，含β2微球蛋白、NT-proBNP等专项监测）。

方案快速选择指南

✅ 预算≤10万元/年：优选保守治疗+严密随访； ✅ 预算20–30万元且符合适应证：优先ASCT（5年生存率提升至65%）； ✅ 晚期/高龄/多器官受累：氯苯唑酸+个体化透析支持，兼顾生活质量与成本效益。